Register
Login:
Share:
Email Facebook Twitter

SAR Share Chat - RSS Feed

Sareum Share Chat (SAR)



Share Price: 0.50Bid: 0.45Ask: 0.55Change: 0.025 (+5.26%)Riser - Sareum
Spread: 0.10Spread as %: 22.22%Open: 0.475High: 0.50Low: 0.475Yesterday’s Close: 0.475


Share Discussion for Sareum (SAR)


Thread ViewThread View
Please Login or Register to post messages
Posts per page:


notalot
Posts: 519
Off Topic
Opinion:No Opinion
Price:0.53
View Thread (2)
RE: buys and sells
6 Mar '14
Or to put it another way, if your buy shows as a sell, you probably got a good price
 
BOOKMAN
Posts: 941
Off Topic
Opinion:No Opinion
Price:0.53
Take part
6 Mar '14
Sareum's pipeline is built on the expertise of its founders in pre-clinical drug discovery, particularly in the field of cancer. Sareum operates as a "virtual" research organisation i.e. all our research is carried out in the laboratories of collaborators or third-party providers. This enables us to access drug discovery expertise throughout the world with a very flexible cost base.
Sareum concentrates its research on targeted small molecule therapeutics. Targeted cancer therapies disrupt specific biochemical processes necessary for tumour growth and survival. Because these processes are specific to cancer cells, targeted therapies may be more effective than other types of treatments, such as chemotherapy and radiotherapy, and less harmful to normal cells. Small molecule therapeutics (as opposed to "biological" drugs such as antibodies) are able to penetrate into the interior of a cancer cell and thus can be targeted at the full range of processes in a biochemical pathway. Small molecule therapeutics also have the potential of being able to be administered orally (e.g. as a pill) rather than by injection.

Our strategy is to focus on developing best in class therapies where pre-clinical and early clinical data is available to indicate that disrupting the targeted biochemical process will indeed prevent tumour growth and survival without significant side-effects, and to indicate whether or not the therapy needs to be administered in combination with additional cancer therapies.

Cancer cells differ from normal cells in many different ways. In particular, cancer cells divide and grow much more rapidly than normal cells. Biochemical processes targeted by Sareum that control cell growth and division include Checkpoint Kinase 1 (Chk1), Aurora Kinase (Aurora), FMS-like Tyrosine Kinase 3 (FLT3), Anaplastic Lymphoma Kinase (ALK), Polo-Like Kinase (PLK) and B-raf. Once a solid tumour reaches a certain size, it needs to be connected to the body's blood and lymph systems to receive nutrients and remove waste. Vascular Endothelial Growth Factor Receptor 3 Kinase, (VEGFR-3, sometimes referred to as Fms-like Tyrosine Kinase 4, FLT4) is importantly involved in the generation of new blood and lymph vessels to a tumour. VEGFR-3 is also involved in the control of metastasis, which is the main cause of death in cancer patients. Many cancer cells are highly dependent on fatty acid levels of which Fatty Acid Synthase (FASN) is a key regulator.

Kinase enzymes are also involved in the control of the immune response. FMS-like Tyrosine Kinase 3 (FLT3) is implicated in the maturation of dendritic cells, implicated in multiple sclerosis, rheumatoid arthritis and other auto-immune diseases. Tyrosine Kinase 2 (TYK2) controls the JAK-STAT pathway which is over-activated in many auto-immune disorders, including rheumatoid arthritis, psoriasis and Crohn's disease.
Londonwolfie
Posts: 453
Off Topic
Opinion:No Opinion
Price:0.45
View Thread (2)
buys and sells
6 Mar '14
I think it should be a requirement of site membership that people have to sign an agreement slip saying that they understand how this is calculated.

Lse simply gets the number of shares and price details from the exchange. It then has the simplest of calculations to determine its guess at whether it's a buy or sell.

Take yesterday. The quoted spread was 0.50 - 0.55 all day. Provided you dealt within the NMS, the real spread was about 0.501 - 0.522. So, using LSE's sophisticated algo programme, any trade below 0.525 was deemed a sell. Nothing sinister. Nothing manipulative by MM's.
guldfingarz1
Posts: 476
Premium Chat Member
Observation
Opinion:Strong Buy
Price:0.53
hiding buys
5 Mar '14
more like 6mil of buys today, not sure why the buys are going through as sells only guess is to keep the s.p artificially low..
paulus47
Posts: 151
Off Topic
Opinion:Buy
Price:0.53
SP
5 Mar '14
That's right, 2.647m buys today, so far
schlepper
Posts: 1,826
Observation
Opinion:No Opinion
Price:0.53
SP
5 Mar '14
Anything above 0.51 is actually a BUY........I know as 1 of them is mine...most reported wrong here for a while now...GLA.
jamster
Posts: 1,571
Off Topic
Opinion:No Opinion
Price:0.53
View Thread (2)
RE: news ?
5 Mar '14
shhhhh! No more research updates please - the SP just cant handle it :) Just let me know when we land something that generates revenue.
mcfcnige
Posts: 2,819
Off Topic
Opinion:No Opinion
Price:0.53
View Thread (2)
news ?
5 Mar '14
did i read somewhere that thee was news due this month on one of the programmes ?
jamster
Posts: 1,571
Off Topic
Opinion:No Opinion
Price:0.53
popular
4 Mar '14
today!
BOOKMAN
Posts: 941
Off Topic
Opinion:No Opinion
Price:0.53
View Thread (2)
RE: SAR
4 Mar '14
false alarm why do the shares say 14% down before the market even opens then goes back to normal nearly had a heart attack lool



Share Trading BrochureRequest your Free brochures on share dealing, spread betting and CFDs

Sign up for Live Prices
Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.